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Evidenced-based guidelines for management of infants and children with community-acquired pneumonia
(CAP) were prepared by an expert panel comprising clinicians and investigators representing community
pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine,
infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and
subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in
both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive
surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted.

EXECUTIVE SUMMARY
Guidelines for the management of community-acquired
pneumonia (CAP) in adults have been demonstrated to
decrease morbidity and mortality rates [1, 2]. These
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guidelines were created to assist the clinician in the care
of a child with CAP. They do not represent the only
approach to diagnosis and therapy; there is considerable
variation among children in the clinical course of pediatric CAP, even with infection caused by the same
pathogen. The goal of these guidelines is to decrease
morbidity and mortality rates for CAP in children by
presenting recommendations for clinical management
that can be applied in individual cases if deemed appropriate by the treating clinician.
This document is designed to provide guidance in the
care of otherwise healthy infants and children and addresses practical questions of diagnosis and management
of CAP evaluated in outpatient (offices, urgent care
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clinics, emergency departments) or inpatient settings in the
United States. Management of neonates and young infants
through the first 3 months, immunocompromised children,
children receiving home mechanical ventilation, and children with
chronic conditions or underlying lung disease, such as cystic fibrosis, are beyond the scope of these guidelines and are not discussed.
Summarized below are the recommendations made in the
new 2011 pediatric CAP guidelines. The panel followed a process
used in the development of other Infectious Diseases Society of
America (IDSA) guidelines, which included a systematic
weighting of the quality of the evidence and the grade of the
recommendation [3] (Table 1). A detailed description of the
methods, background, and evidence summaries that support
each of the recommendations can be found in the full text of the
guidelines.
SITE-OF-CARE MANAGEMENT DECISIONS
I. When Does a Child or Infant With CAP Require Hospitalization?

Recommendations
1. Children and infants who have moderate to severe CAP,
as defined by several factors, including respiratory distress and
hypoxemia (sustained saturation of peripheral oxygen [SpO2],
,90 % at sea level) (Table 3) should be hospitalized for
management, including skilled pediatric nursing care. (strong
recommendation; high-quality evidence)
2. Infants less than 3–6 months of age with suspected
bacterial CAP are likely to benefit from hospitalization. (strong
recommendation; low-quality evidence)
3. Children and infants with suspected or documented
CAP caused by a pathogen with increased virulence, such as
community-associated methicillin-resistant Staphylococcus aureus
(CA-MRSA) should be hospitalized. (strong recommendation; lowquality evidence)
4. Children and infants for whom there is concern about
careful observation at home or who are unable to comply with
therapy or unable to be followed up should be hospitalized.
(strong recommendation; low-quality evidence)

II. When Should a Child With CAP Be Admitted to an Intensive
Care Unit (ICU) or a Unit With Continuous Cardiorespiratory
Monitoring?

child acutely requires use of noninvasive positive pressure
ventilation (eg, continuous positive airway pressure or bilevel
positive airway pressure). (strong recommendation; very lowquality evidence)
7. A child should be admitted to an ICU or a unit with
continuous cardiorespiratory monitoring capabilities if the child
has impending respiratory failure. (strong recommendation;
moderate-quality evidence)
8. A child should be admitted to an ICU or a unit with
continuous cardiorespiratory monitoring capabilities if the child
has sustained tachycardia, inadequate blood pressure, or need for
pharmacologic support of blood pressure or perfusion. (strong
recommendation; moderate-quality evidence)
9. A child should be admitted to an ICU if the pulse
oximetry measurement is ,92% on inspired oxygen of $0.50.
(strong recommendation; low-quality evidence)
10. A child should be admitted to an ICU or a unit with
continuous cardiorespiratory monitoring capabilities if the
child has altered mental status, whether due to hypercarbia or
hypoxemia as a result of pneumonia. (strong recommendation;
low-quality evidence)
11. Severity of illness scores should not be used as the sole
criteria for ICU admission but should be used in the context of
other clinical, laboratory, and radiologic findings. (strong
recommendation; low-quality evidence)
DIAGNOSTIC TESTING FOR PEDIATRIC CAP
III. What Diagnostic Laboratory and Imaging Tests Should Be
Used in a Child With Suspected CAP in an Outpatient or
Inpatient Setting?

Recommendations
Microbiologic Testing
Blood Cultures: Outpatient
12. Blood cultures should not be routinely performed in
nontoxic, fully immunized children with CAP managed in the
outpatient setting. (strong recommendation; moderate-quality
evidence)
13. Blood cultures should be obtained in children who fail to
demonstrate clinical improvement and in those who have
progressive symptoms or clinical deterioration after initiation
of antibiotic therapy (strong recommendation; moderate-quality
evidence).

Recommendations

Blood Cultures: Inpatient

5. A child should be admitted to an ICU if the child requires
invasive ventilation via a nonpermanent artificial airway (eg,
endotracheal tube). (strong recommendation; high-quality
evidence)
6. A child should be admitted to an ICU or a unit with
continuous cardiorespiratory monitoring capabilities if the

14. Blood cultures should be obtained in children requiring
hospitalization for presumed bacterial CAP that is moderate to
severe, particularly those with complicated pneumonia. (strong
recommendation; low-quality evidence)
15. In improving patients who otherwise meet criteria
for discharge, a positive blood culture with identification or
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Table 1. Strength of Recommendations and Quality of Evidence
Strength of recommendation
Clarity of balance between
and quality of evidence
desirable and undesirable effects

Methodologic quality of supporting
evidence (examples)

Implications

Strong recommendation
Recommendation can apply to
most patients in most
circumstances; further
research is unlikely to change
our confidence in the
estimate of effect.
Recommendation can apply to
most patients in most
circumstances; further
research (if performed) is
likely to have an important
impact on our confidence in
the estimate of effect and
may change the estimate.

High-quality evidence

Desirable effects clearly
outweigh undesirable effects,
or vice versa

Consistent evidence from wellperformed RCTsa or exceptionally
strong evidence from unbiased
observational studies

Moderate-quality evidence

Desirable effects clearly
outweigh undesirable effects,
or vice versa

Evidence from RCTs with important
limitations (inconsistent results,
methodologic flaws, indirect, or
imprecise) or exceptionally strong
evidence from unbiased
observational studies

Low-quality evidence

Desirable effects clearly
outweigh undesirable effects,
or vice versa

Evidence for $1 critical outcome
from observational studies, RCTs
with serious flaws or indirect
evidence

Recommendation may change
when higher quality evidence
becomes available; further
research (if performed) is
likely to have an important
impact on our confidence in
the estimate of effect and is
likely to change the estimate.

Very low-quality evidence
(rarely applicable)

Desirable effects clearly
outweigh undesirable effects,
or vice versa

Evidence for $1 critical outcome
from unsystematic clinical
observations or very indirect
evidence

Recommendation may change
when higher quality evidence
becomes available; any
estimate of effect for $1
critical outcome is very
uncertain.

High-quality evidence

Desirable effects closely
balanced with undesirable
effects

Consistent evidence from wellperformed RCTs or exceptionally
strong evidence from unbiased
observational studies

Moderate-quality evidence

Desirable effects closely
balanced with undesirable
effects

Evidence from RCTs with important
limitations (inconsistent results,
methodologic flaws, indirect, or
imprecise) or exceptionally strong
evidence from unbiased
observational studies

Low-quality evidence

Uncertainty in the estimates of
desirable effects, harms, and
burden; desirable effects,
harms, and burden may be
closely balanced

Evidence for $1 critical outcome
from observational studies, from
RCTs with serious flaws or indirect
evidence

The best action may differ
depending on circumstances
or patients or societal values;
further research is unlikely to
change our confidence in the
estimate of effect.
Alternative approaches are likely
to be better for some patients
under some circumstances;
further research (if performed)
is likely to have an important
impact on our confidence in
the estimate of effect and
may change the estimate.
Other alternatives may be equally
reasonable; further research is
very likely to have an important
impact on our confidence in the
estimate of effect and is likely
to change the estimate.

Very low-quality evidence

Major uncertainty in estimates
of desirable effects, harms,
and burden; desirable effects
may or may not be balanced
with undesirable effects
may be closely balanced

Evidence for $1 critical outcome from Other alternatives may be equally
unsystematic clinical observations or
reasonable; any estimate of
2very indirect evidence
effect, for at $1 critical
outcome, is very uncertain.

Weak recommendation

a

RCTs, randomized controlled trials.
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Table 2. Complications Associated With Community-Acquired
Pneumonia
Pulmonary
Pleural effusion or empyema
Pneumothorax

Sputum Gram Stain and Culture
18. Sputum samples for culture and Gram stain should be
obtained in hospitalized children who can produce sputum.
(weak recommendation; low-quality evidence)
Urinary Antigen Detection Tests

Lung abscess
Bronchopleural fistula

19. Urinary antigen detection tests are not recommended
for the diagnosis of pneumococcal pneumonia in children;
false-positive tests are common. (strong recommendation; highquality evidence)

Necrotizing pneumonia
Acute respiratory failure
Metastatic
Meningitis
Central nervous system abscess
Pericarditis
Endocarditis
Osteomyelitis
Septic arthritis
Systemic
Systemic inflammatory response syndrome or sepsis
Hemolytic uremic syndrome

susceptibility results pending should not routinely preclude
discharge of that patient with appropriate oral or intravenous
antimicrobial therapy. The patient can be discharged if close
follow-up is assured. (weak recommendation; low-quality evidence)
Follow-up Blood Cultures
16. Repeated blood cultures in children with clear clinical
improvement are not necessary to document resolution of
pneumococcal bacteremia. (weak recommendation; low-quality
evidence)
17. Repeated blood cultures to document resolution of
bacteremia should be obtained in children with bacteremia
caused by S. aureus, regardless of clinical status. (strong
recommendation; low-quality evidence)

Table 3. Criteria for Respiratory Distress in Children With
Pneumonia
Signs of Respiratory Distress
1. Tachypnea, respiratory rate, breaths/mina
Age 0–2 months: .60
Age 2–12 months: .50
Age 1–5 Years: .40

Testing For Viral Pathogens
20. Sensitive and specific tests for the rapid diagnosis of
influenza virus and other respiratory viruses should be used in
the evaluation of children with CAP. A positive influenza test
may decrease both the need for additional diagnostic studies
and antibiotic use, while guiding appropriate use of antiviral
agents in both outpatient and inpatient settings. (strong
recommendation; high-quality evidence)
21. Antibacterial therapy is not necessary for children, either
outpatients or inpatients, with a positive test for influenza virus
in the absence of clinical, laboratory, or radiographic findings
that suggest bacterial coinfection. (strong recommendation;
high-quality evidence).
22. Testing for respiratory viruses other than influenza virus
can modify clinical decision making in children with suspected
pneumonia, because antibacterial therapy will not routinely be
required for these children in the absence of clinical, laboratory,
or radiographic findings that suggest bacterial coinfection.
(weak recommendation; low-quality evidence)
Testing for Atypical Bacteria
23. Children with signs and symptoms suspicious for
Mycoplasma pneumoniae should be tested to help guide
antibiotic selection. (weak recommendation; moderate-quality
evidence)
24. Diagnostic testing for Chlamydophila pneumoniae is not
recommended as reliable and readily available diagnostic tests
do not currently exist. (strong recommendation; high-quality
evidence)
Ancillary Diagnostic Testing
Complete Blood Cell Count

Age .5 Years: .20
2. Dyspnea
3. Retractions (suprasternal, intercostals, or subcostal)
4. Grunting
5. Nasal flaring
6. Apnea
7. Altered mental status
8. Pulse oximetry measurement ,90% on room air
a
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25. Routine measurement of the complete blood cell count is
not necessary in all children with suspected CAP managed in the
outpatient setting, but in those with more serious disease it may
provide useful information for clinical management in the
context of the clinical examination and other laboratory and
imaging studies. (weak recommendation; low-quality evidence)
26. A complete blood cell count should be obtained for
patients with severe pneumonia, to be interpreted in the context

of the clinical examination and other laboratory and imaging
studies. (weak recommendation; low-quality evidence)

Table 4. Criteria for CAP Severity of Illness in Children with
Community-Acquired Pneumonia

Acute-Phase Reactants

Criteria

27. Acute-phase reactants, such as the erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP)
concentration, or serum procalcitonin concentration, cannot
be used as the sole determinant to distinguish between viral and
bacterial causes of CAP. (strong recommendation; high-quality
evidence)
28. Acute-phase reactants need not be routinely measured
in fully immunized children with CAP who are managed as
outpatients, although for more serious disease, acute-phase
reactants may provide useful information for clinical
management. (strong recommendation; low-quality evidence)
29. In patients with more serious disease, such as those
requiring hospitalization or those with pneumonia-associated
complications, acute-phase reactants may be used in
conjunction with clinical findings to assess response to
therapy. (weak recommendation; low-quality evidence)

Major criteria

Pulse Oximetry

Invasive mechanical ventilation
Fluid refractory shock
Acute need for NIPPV
hypoxemia requiring FiO2 greater than inspired concentration or
flow feasible in general care area
Minor criteria
Respiratory rate higher than WHO classification for age
Apnea
Increased work of breathing (eg, retractions, dyspnea, nasal flaring,
grunting)
PaO2/FiO2 ratio ,250
Multilobar infiltrates
PEWS score .6
Altered mental status
Hypotension
Presence of effusion
Comorbid conditions (eg, HgbSS, immunosuppression,
immunodeficiency)
Unexplained metabolic acidosis

30. Pulse oximetry should be performed in all children with
pneumonia and suspected hypoxemia. The presence of
hypoxemia should guide decisions regarding site of care and
further diagnostic testing. (strong recommendation; moderatequality evidence)

Modified from Infectious Diseases Society of America/American Thoracic
Society consensus guidelines on the management of community-acquired
pneumonia in adults [27, table 4]. Clinician should consider care in an intensive
care unit or a unit with continuous cardiorespiratory monitoring for the child
having $1 major or $2 minor criteria.
Abbreviations: FiO2, fraction of inspired oxygen; HgbSS, Hemoglobin SS
disease; NIPPV, noninvasive positive pressure ventilation; PaO2, arterial
oxygen pressure; PEWS, Pediatric Early Warning Score [70].

Chest Radiography
Initial Chest Radiographs: Outpatient
31. Routine chest radiographs are not necessary for the
confirmation of suspected CAP in patients well enough to be
treated in the outpatient setting (after evaluation in the
office, clinic, or emergency department setting). (strong
recommendation; high-quality evidence)
32. Chest radiographs, posteroanterior and lateral, should be
obtained in patients with suspected or documented hypoxemia
or significant respiratory distress (Table 3) and in those with
failed initial antibiotic therapy to verify the presence or absence
of complications of pneumonia, including parapneumonic
effusions, necrotizing pneumonia, and pneumothorax. (strong
recommendation; moderate-quality evidence)
Initial Chest Radiographs: Inpatient
33. Chest radiographs (posteroanterior and lateral) should be
obtained in all patients hospitalized for management of CAP to
document the presence, size, and character of parenchymal
infiltrates and identify complications of pneumonia that may
lead to interventions beyond antimicrobial agents and supportive
medical therapy. (strong recommendation; moderate-quality
evidence)

Follow-up Chest Radiograph
34. Repeated chest radiographs are not routinely required in
children who recover uneventfully from an episode of CAP.
(strong recommendation; moderate-quality evidence)
35. Repeated chest radiographs should be obtained in
children who fail to demonstrate clinical improvement and
in those who have progressive symptoms or clinical
deterioration within 48–72 hours after initiation of
antibiotic therapy. (strong recommendation; moderate-quality
evidence)
36. Routine daily chest radiography is not recommended
in children with pneumonia complicated by parapneumonic
effusion after chest tube placement or after videoassisted thoracoscopic surgery (VATS), if they remain
clinically stable. (strong recommendation; low-quality
evidence)
37. Follow-up chest radiographs should be obtained in
patients with complicated pneumonia with worsening
respiratory distress or clinical instability, or in those with
persistent fever that is not responding to therapy over 48-72
hours. (strong recommendation; low-quality evidence)
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38. Repeated chest radiographs 4–6 weeks after the
diagnosis of CAP should be obtained in patients with
recurrent pneumonia involving the same lobe and in
patients with lobar collapse at initial chest radiography
with suspicion of an anatomic anomaly, chest mass, or
foreign body aspiration. (strong recommendation; moderatequality evidence)
IV. What Additional Diagnostic Tests Should Be Used in a Child
With Severe or Life-Threatening CAP?

Recommendations
39. The clinician should obtain tracheal aspirates for Gram
stain and culture, as well as clinically and epidemiologically
guided testing for viral pathogens, including influenza virus, at
the time of initial endotracheal tube placement in children
requiring mechanical ventilation. (strong recommendation; lowquality evidence)
40. Bronchoscopic or blind protected specimen brush
sampling, bronchoalveolar lavage (BAL), percutaneous lung
aspiration, or open lung biopsy should be reserved for the
immunocompetent child with severe CAP if initial diagnostic tests
are not positive. (weak recommendation; low-quality evidence)

ANTI-INFECTIVE TREATMENT
V. Which Anti-Infective Therapy Should Be Provided to a Child
With Suspected CAP in Both Outpatient and Inpatient Settings?

Recommendations
Outpatients
41. Antimicrobial therapy is not routinely required for
preschool-aged children with CAP, because viral pathogens are
responsible for the great majority of clinical disease. (strong
recommendation; high-quality evidence)
42. Amoxicillin should be used as first-line therapy for
previously healthy, appropriately immunized infants and
preschool children with mild to moderate CAP suspected to
be of bacterial origin. Amoxicillin provides appropriate
coverage for Streptococcus pneumoniae, the most prominent
invasive bacterial pathogen. Table 5 lists preferred agents and
alternative agents for children allergic to amoxicillin (strong
recommendation; moderate-quality evidence)
43. Amoxicillin should be used as first-line therapy for
previously healthy appropriately immunized school-aged
children and adolescents with mild to moderate CAP for
S. pneumoniae, the most prominent invasive bacterial
pathogen. Atypical bacterial pathogens (eg, M. pneumoniae),
and less common lower respiratory tract bacterial pathogens, as
discussed in the Evidence Summary, should also be considered in
management decisions. (strong recommendation; moderatequality evidence)
622
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44. Macrolide antibiotics should be prescribed for treatment
of children (primarily school-aged children and adolescents)
evaluated in an outpatient setting with findings compatible
with CAP caused by atypical pathogens. Laboratory testing for
M. pneumoniae should be performed if available in a clinically
relevant time frame. Table 5 lists preferred and alternative agents
for atypical pathogens. (weak recommendation; moderate-quality
evidence)
45. Influenza antiviral therapy (Table 6) should be
administered as soon as possible to children with moderate
to severe CAP consistent with influenza virus infection during
widespread local circulation of influenza viruses, particularly
for those with clinically worsening disease documented at the
time of an outpatient visit. Because early antiviral treatment has
been shown to provide maximal benefit, treatment should not be
delayed until confirmation of positive influenza test results.
Negative results of influenza diagnostic tests do not conclusively
exclude influenza disease. Treatment after 48 hours of
symptomatic infection may still provide clinical benefit to those
with more severe disease. (strong recommendation; moderatequality evidence)
Inpatients
46. Ampicillin or penicillin G should be administered to the
fully immunized infant or school-aged child admitted to
a hospital ward with CAP when local epidemiologic data
document lack of substantial high-level penicillin resistance for
invasive S. pneumoniae. Other antimicrobial agents for empiric
therapy are provided in Table 7. (strong recommendation;
moderate-quality evidence)
47. Empiric therapy with a third-generation parenteral
cephalosporin (ceftriaxone or cefotaxime) should be
prescribed for hospitalized infants and children who are
not fully immunized, in regions where local epidemiology of
invasive pneumococcal strains documents high-level penicillin
resistance, or for infants and children with life-threatening
infection, including those with empyema (Table 7). Non–
b-lactam agents, such as vancomycin, have not been shown to
be more effective than third-generation cephalosporins in
the treatment of pneumococcal pneumonia for the degree
of resistance noted currently in North America. (weak
recommendation; moderate-quality evidence)
48. Empiric combination therapy with a macrolide (oral or
parenteral), in addition to a b-lactam antibiotic, should be
prescribed for the hospitalized child for whom M. pneumoniae
and C. pneumoniae are significant considerations; diagnostic
testing should be performed if available in a clinically relevant
time frame (Table 7). (weak recommendation; moderate-quality
evidence)
49. Vancomycin or clindamycin (based on local susceptibility
data) should be provided in addition to b-lactam therapy if

Table 5. Selection of Antimicrobial Therapy for Specific Pathogens

Pathogen

Parenteral therapy

Streptococcus pneumoniae with Preferred: ampicillin (150–200 mg/kg/day every
MICs for penicillin #2.0 lg/mL
6 hours) or penicillin (200 000–250 000 U/kg/day
every 4–6 h);
Alternatives: ceftriaxone
(50–100 mg/kg/day every 12–24 hours) (preferred
for parenteral outpatient therapy) or cefotaxime
(150 mg/kg/day every 8 hours); may also be
effective: clindamycin (40 mg/kg/day every
6–8 hours) or vancomycin (40–60 mg/kg/day every
6–8 hours)

S. pneumoniae resistant to
penicillin, with MICs
$4.0 lg/mL

Group A Streptococcus

Stapyhylococcus aureus,
methicillin susceptible
(combination therapy not
well studied)

S. aureus, methicillin resistant,
susceptible to clindamycin
(combination therapy not
well-studied)

S. aureus, methicillin resistant,
resistant to clindamycin
(combination therapy not
well studied)

Preferred: ceftriaxone (100 mg/kg/day every
12–24 hours);
Alternatives: ampicillin
(300–400 mg/kg/day every 6 hours), levofloxacin
(16–20 mg/kg/day every 12 hours for children
6 months to 5 years old and 8–10 mg/kg/day
once daily for children 5–16 years old; maximum
daily dose, 750 mg), or linezolid (30 mg/kg/day
every 8 hours for children ,12 years old and
20 mg/kg/day every 12 hours for children $12 years
old); may also be effective: clindamycina
(40 mg/kg/day every 6–8 hours) or vancomycin
(40–60 mg/kg/day every 6–8 hours)
Preferred: intravenous penicillin (100 000–250 000
U/kg/day every 4–6 hours) or ampicillin
(200 mg/kg/day every 6 hours);

Oral therapy (step-down therapy
or mild infection)
Preferred: amoxicillin (90 mg/kg/day in
2 doses or 45 mg/kg/day in 3 doses);
Alternatives: second- or third-generation
cephalosporin (cefpodoxime, cefuroxime,
cefprozil); oral levofloxacin, if susceptible
(16–20 mg/kg/day in 2 doses for children
6 months to 5 years old and 8–10 mg/kg/day
once daily for children 5 to 16 years old;
maximum daily dose, 750 mg) or oral
linezolid (30 mg/kg/day in 3 doses for
children ,12 years old and 20 mg/kg/day
in 2 doses for children $12 years old)
Preferred: oral levofloxacin (16–20 mg/kg/day
in 2 doses for children 6 months to 5 years
and 8–10 mg/kg/day once daily for children
5–16 years, maximum daily dose, 750 mg),
if susceptible, or oral linezolid (30 mg/kg/day
in 3 doses for children ,12 years and
20 mg/kg/day in 2 doses for children
$12 years);
Alternative: oral clindamycina
(30–40 mg/kg/day in 3 doses)

Preferred: amoxicillin (50–75 mg/kg/day in
2 doses), or penicillin V (50–75 mg/kg/day in
3 or 4 doses);

Alternatives: ceftriaxone (50–100 mg/kg/day every
12–24 hours) or cefotaxime (150 mg/kg/day every
8 hours); may also be effective: clindamycin, if
susceptible (40 mg/kg/day every 6–8 hours) or
vancomycinb (40–60 mg/kg/day every 6–8 hours)

Alternative: oral clindamycina
(40 mg/kg/day in 3 doses)

Preferred: cefazolin (150 mg/kg/day every 8 hours) or
semisynthetic penicillin, eg oxacillin
(150–200 mg/kg/day every 6–8 hours);

Preferred: oral cephalexin (75–100 mg/kg/day
in 3 or 4 doses);

Alternative: oral clindamycina
(30–40 mg/kg/day in 3 or 4 doses)
Alternatives: clindamycina (40 mg/kg/day every
6–8 hours) or >vancomycin (40–60 mg/kg/day
every 6–8 hours)
Preferred: vancomycin (40–60 mg/kg/day every
Preferred: oral clindamycin (30–40 mg/kg/day
6–8 hours or dosing to achieve an AUC/MIC ratio of
in 3 or 4 doses);
.400) or clindamycin (40 mg/kg/day every 6–8 hours);
Alternatives: oral linezolid
Alternatives: linezolid (30 mg/kg/day every 8 hours
(30 mg/kg/day in 3 doses for children
for children ,12 years old and 20 mg/kg/day every
,12 years and 20 mg/kg/day in 2 doses
12 hours for children $12 years old)
for children $12 years)
Preferred: vancomycin (40–60 mg/kg/day every
6-8 hours or dosing to achieve an AUC/MIC ratio of
.400);
Alternatives: linezolid (30 mg/kg/day every
8 hours for children ,12 years old and 20 mg/kg/day
every 12 hours for children $12 years old)

Preferred: oral linezolid (30 mg/kg/day in
3 doses for children ,12 years and
20 mg/kg/day in 2 doses for children
$12 years old);
Alternatives: none; entire treatment course with
parenteral therapy may be required
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Table 5. (Continued)
Pathogen

Oral therapy (step-down therapy
or mild infection)

Parenteral therapy

Haemophilus influenza, typeable Preferred: intravenous ampicillin (150-200 mg/kg/day
(A-F) or nontypeable
every 6 hours) if b-lactamase negative, ceftriaxone
(50–100 mg/kg/day every 12-24 hours) if b-lactamase
producing, or cefotaxime (150 mg/kg/day every
8 hours);
Alternatives: intravenous ciprofloxacin (30 mg/kg/day
every 12 hours) or intravenous levofloxacin
(16-20 mg/kg/day every 12 hours for
children 6 months to 5 years old
and 8-10 mg/kg/day once daily for children 5 to
16 years old; maximum daily dose, 750 mg)
Mycoplasma pneumoniae

Chlamydia trachomatis or
Chlamydophila pneumoniae

Preferred: amoxicillin (75-100 mg/kg/day in
3 doses) if b-lactamase negative) or
amoxicillin clavulanate (amoxicillin
component, 45 mg/kg/day in 3 doses or
90 mg/kg/day in 2 doses) if b-lactamase
producing;
Alternatives: cefdinir, cefixime,
cefpodoxime, or ceftibuten

Preferred: intravenous azithromycin
(10 mg/kg on days 1 and 2 of therapy;
transition to oral therapy if possible);

Preferred: azithromycin (10 mg/kg on day 1,
followed by 5 mg/kg/day once daily on
days 2–5);

Alternatives: intravenous erythromycin lactobionate
(20 mg/kg/day every 6 hours) or levofloxacin
(16-20 mg/kg/day every 12 hours; maximum daily
dose, 750 mg)

Alternatives: clarithromycin
(15 mg/kg/day in 2 doses) or oral
erythromycin (40 mg/kg/day in 4 doses);
for children .7 years old, doxycycline
(2–4 mg/kg/day in 2 doses; for adolescents
with skeletal maturity, levofloxacin
(500 mg once daily) or moxifloxacin
(400 mg once daily)

Preferred: intravenous azithromycin
(10 mg/kg on days 1 and 2 of therapy;
transition to oral therapy if possible);

Preferred: azithromycin (10 mg/kg on day 1,
followed by 5 mg/kg/day once daily
days 2–5);

Alternatives: intravenous erythromycin lactobionate
(20 mg/kg/day every 6 hours) or levofloxacin
(16-20 mg/kg/day in 2 doses for children 6 months
to 5 years old and 8-10 mg/kg/day once daily for
children 5 to 16 years old; maximum daily dose,
750 mg)

Alternatives: clarithromycin
(15 mg/kg/day in 2 doses) or oral
erythromycin (40 mg/kg/day in 4 doses);
for children .7 years old, doxycycline
(2-4 mg/kg/day in 2 doses); for adolescents
with skeletal maturity, levofloxacin
(500 mg once daily) or moxifloxacin
(400 mg once daily)

Doses for oral therapy should not exceed adult doses.
Abbreviations: AUC, area under the time vs. serum concentration curve; MIC, minimum inhibitory concentration.
a

Clindamycin resistance appears to be increasing in certain geographic areas among S. pneumoniae and S. aureus infections.

b

For b-lactam–allergic children.

clinical, laboratory, or imaging characteristics are consistent
with infection caused by S. aureus (Table 7). (strong
recommendation; low-quality evidence)

53. Treatment for the shortest effective duration will
minimize exposure of both pathogens and normal microbiota
to antimicrobials and minimize the selection for resistance.
(strong recommendation; low-quality evidence)

VI. How Can Resistance to Antimicrobials Be Minimized?

Recommendations
50. Antibiotic exposure selects for antibiotic resistance;
therefore, limiting exposure to any antibiotic, whenever possible,
is preferred. (strong recommendation; moderate-quality evidence)
51. Limiting the spectrum of activity of antimicrobials to
that specifically required to treat the identified pathogen is
preferred. (strong recommendation; low-quality evidence)
52. Using the proper dosage of antimicrobial to be able to
achieve a minimal effective concentration at the site of infection
is important to decrease the development of resistance. (strong
recommendation; low-quality evidence)
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VII. What Is the Appropriate Duration of Antimicrobial Therapy
for CAP?

Recommendations
54. Treatment courses of 10 days have been best studied,
although shorter courses may be just as effective, particularly
for more mild disease managed on an outpatient basis. (strong
recommendation; moderate-quality evidence)
55. Infections caused by certain pathogens, notably CAMRSA, may require longer treatment than those caused by
S. pneumoniae. (strong recommendation; moderate-quality
evidence)

Table 6. Influenza Antiviral Therapy
Dosing recommendations
Prophylaxisa

Treatment
Drug
Oseltamivir
(Tamiflu)

Formulation
75-mg capsule;
60 mg/5 mL
Suspension

Children

Adults

$24 months old:
4 mg/kg/day in
2 doses, for a
5-day treatment
course

150 mg/day in
2 doses for
5 days

Children
#15 kg: 30 mg/day; .15 to
23 kg: 45 mg/day; .23 to
40 kg: 60 mg/day; .40 kg:
75 mg/day (once daily in
each group)

Adults
75 mg/day
once daily

#15 kg: 60 mg/day;
.15 to 23 kg:
90 mg/day; .23 to
40 kg: 120 mg/day;
.40 kg: 150 mg/day
(divided into 2 doses
for each group)
9–23 months old:
7 mg/kg/day in
2 doses; 0–8 months
old: 6 mg/kg/day in
2 doses; premature
infants: 2 mg/kg/day
in 2 doses
Zanamivir
(Relenza)

5 mg per inhalation, $7 years old: 2 inhalations
using a Diskhaler
(10 mg total per dose),
twice daily for 5 days

100-mg tablet;
Amantadine
50 mg/5 mL
(Symmetrel)b
suspension

Rimantadine
(Flumadine)b

9–23 months old: 3.5 mg/kg
once daily; 3–8 months old:
3 mg/kg once daily; not
routinely recommended for
infants ,3 months old
owing to limited data in
this age group

100-mg tablet;
50 mg/5 mL
suspension

1–9 years old: 5–8 mg/kg/day
as single daily dose or in
2 doses, not to exceed
150 mg/day; 9–12 years old:
200 mg/day in 2 doses (not
studied as single daily dose)

2 inhalations
$5 years old: 2 inhalations
(10 mg total per
(10 mg total per dose),
dose), twice daily
once daily for 10 days
for 5 days
200 mg/day, as
single daily dose
or in 2 doses

Not FDA approved for
200 mg/day, either
treatment in children, but
as a single daily
published data exist on safety
dose, or divided
and efficacy in children;
into 2 doses
suspension: 1–9 years old:
6.6 mg/kg/day (maximum
150 mg/kg/day) in 2 doses;
$10 years old: 200 mg/day, as
single daily dose or in 2 doses

1–9 years old:
same as
treatment dose;
9–12 years old:
same as
treatment dose

2 inhalations
(10 mg total
per dose),
once daily
for 10 days
Same as
treatment
dose

FDA approved for prophylaxis 200 mg/day,
down to 12 months of age.
as single
1–9 years old: 5 mg/kg/day
daily dose
once daily, not to exceed
or in
150 mg; $10 years old:
2 doses
200 mg/day as single daily
dose or in 2 doses

NOTE. Check Centers for Disease Control and Prevention Website (http://www.flu.gov/) for current susceptibility data.
a
In children for whom prophylaxis is indicated, antiviral drugs should be continued for the duration of known influenza activity in the community because of the
potential for repeated and unknown exposures or until immunity can be achieved after immunization.
b
Amantadine and rimantadine should be used for treatment and prophylaxis only in winter seasons during which a majority of influenza A virus strains
isolated are adamantine susceptible; the adamantanes should not be used for primary therapy because of the rapid emergence of resistance. However,
for patients requiring adamantane therapy, a treatment course of 7 days is suggested, or until 24–48 hours after the disappearance of signs and
symptoms.

VIII. How Should the Clinician Follow the Child With CAP for the
Expected Response to Therapy?

ADJUNCTIVE SURGICAL AND NON–
ANTI-INFECTIVE THERAPY FOR PEDIATRIC CAP

Recommendation
56. Children on adequate therapy should demonstrate clinical
and laboratory signs of improvement within 48–72 hours. For
children whose condition deteriorates after admission and
initiation of antimicrobial therapy or who show no
improvement within 48–72 hours, further investigation should
be performed. (strong recommendation; moderate-quality evidence)

IX. How Should a Parapneumonic Effusion Be Identified?

Recommendation
57. History and physical examination may be suggestive of
parapneumonic effusion in children suspected of having CAP, but
chest radiography should be used to confirm the presence of
pleural fluid. If the chest radiograph is not conclusive, then
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Table 7. Empiric Therapy for Pediatric Community-Acquired Pneumonia (CAP)
Empiric therapy
Presumed bacterial
pneumonia

Site of care
Outpatient
,5 years old (preschool)

$5 years old

Amoxicillin, oral (90 mg/kg/day in
2 dosesb); alternative: oral
amoxicillin clavulanate (amoxicillin
component, 90 mg/kg/day in
2 dosesb)

Presumed atypical
pneumonia

Presumed influenza
pneumoniaa

Azithromycin oral (10 mg/kg on day 1,
Oseltamivir
followed by 5 mg/kg/day once daily
on days 2–5); alternatives: oral
clarithromycin (15 mg/kg/day in 2
doses for 7-14 days) or oral
erythromycin (40 mg/kg/day in 4 doses)

Oral azithromycin (10 mg/kg on
Oral amoxicillin (90 mg/kg/day in
day 1, followed by 5 mg/kg/day
2 dosesb to a maximum of 4 g/dayc);
for children with presumed bacterial
once daily on days 2–5 to a
CAP who do not have clinical,
maximum of 500 mg on day 1,
laboratory, or radiographic evidence
followed by 250 mg on days 2–5);
that distinguishes bacterial CAP from
alternatives: oral clarithromycin
atypical CAP, a macrolide can be
(15 mg/kg/day in 2 doses to a
added to a b-lactam antibiotic for
maximum of 1 g/day);
empiric therapy; alternative: oral
erythromycin, doxycycline for
amoxicillin clavulanate (amoxicillin
children .7 years old
component, 90 mg/kg/day in 2 dosesb
to a maximum dose of 4000 mg/day,
eg, one 2000-mg tablet twice dailyb)

Oseltamivir or zanamivir
(for children 7 years
and older); alternatives:
peramivir, oseltamivir
and zanamivir
(all intravenous) are
under clinical
investigation in children;
intravenous zanamivir
available for
compassionate use

Inpatient (all ages)d
Fully immunized with
Ampicillin or penicillin G; alternatives:
conjugate vaccines for
ceftriaxone or cefotaxime; addition
Haemophilus influenzae
of vancomycin or clindamycin for
type b and Streptococcus
suspected CA-MRSA
pneumoniae; local
penicillin resistance in
invasive strains of
pneumococcus is minimal

Azithromycin (in addition to b-lactam, if
diagnosis of atypical pneumonia is in
doubt); alternatives: clarithromycin
or erythromycin; doxycycline for
children .7 years old; levofloxacin
for children who have reached
growth maturity, or who cannot
tolerate macrolides

Oseltamivir or zanamivir
(for children $7 years old;
alternatives: peramivir,
oseltamivir and zanamivir
(all intravenous) are under
clinical investigation in
children; intravenous
zanamivir available for
compassionate use

Not fully immunized for H,
influenzae type b and
S. pneumoniae; local
penicillin resistance in
invasive strains of
pneumococcus is
significant

Azithromycin (in addition to b-lactam,
if diagnosis in doubt); alternatives:
clarithromycin or erythromycin;
doxycycline for children .7 years
old; levofloxacin for children who
have reached growth maturity or
who cannot tolerate macrolides

As above

Ceftriaxone or cefotaxime; addition of
vancomycin or clindamycin for
suspected CA-MRSA; alternative:
levofloxacin; addition of vancomycin
or clindamycin for suspected
CA-MRSA

For children with drug allergy to recommended therapy, see Evidence Summary for Section V. Anti-Infective Therapy. For children with a history of possible, nonserious
allergic reactions to amoxicillin, treatment is not well defined and should be individualized. Options include a trial of amoxicillin under medical observation; a trial of an oral
cephalosporin that has substantial activity against S. pneumoniae, such as cefpodoxime, cefprozil, or cefuroxime, provided under medical supervision; treatment with
levofloxacin; treatment with linezolid; treatment with clindamycin (if susceptible); or treatment with a macrolide (if susceptible). For children with bacteremic pneumococcal
pneumonia, particular caution should be exercised in selecting alternatives to amoxicillin, given the potential for secondary sites of infection, including meningitis.
Abbreviation: CA-MRSA, community-associated methicillin-resistant Staphylococcus aureus.
a

See Table 6 for dosages.

b

See text for discussion of dosage recommendations based on local susceptibility data. Twice daily dosing of amoxicillin or amoxicillin clavulanate may be
effective for pneumococci that are susceptible to penicillin.
c

Not evaluated prospectively for safety.

d

See Table 5 for dosages.

further imaging with chest ultrasound or computed tomography
(CT) is recommended. (strong recommendation; high-quality
evidence)

59. The child’s degree of respiratory compromise is an
important factor that determines management of parapneumonic
effusions (Table 8, Figure 1) (strong recommendation; moderatequality evidence)

X. What Factors Are Important in Determining Whether Drainage
of the Parapneumonic Effusion Is Required?

XI. What Laboratory Testing Should Be Performed on Pleural Fluid?

Recommendations

Recommendation

58. The size of the effusion is an important factor that
determines management (Table 8, Figure 1). (strong
recommendation; moderate-quality evidence)

60. Gram stain and bacterial culture of pleural fluid should
be performed whenever a pleural fluid specimen is obtained.
(strong recommendation; high-quality evidence)
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Table 8. Factors Associated with Outcomes and Indication for Drainage of Parapneumonic Effusions

Size of effusion

Risk of poor
outcome

Bacteriology

Tube drainage with or
without fibrinolysis or VATSa

Small: ,10 mm on lateral
decubitus radiograph or
opacifies less than
one-fourth of hemithorax

Bacterial culture and Gram
stain results unknown or
negative

Low

No; sampling of pleural fluid is not
routinely required

Moderate: .10-mm rim of
fluid but opacifies less than
half of the hemithorax

Bacterial culture and/or Gram
stain results negative or
positive (empyema)

Low to moderate

No if the patient has no respiratory compromise
and the pleural fluid is not consistent with
empyema (sampling of pleural fluid by simple
thoracentesis may help determine presence
or absence of empyema and need for a
drainage procedure, and sampling with a
drainage catheter may provide both
diagnostic and therapeutic benefit);
Yes, if the patient has respiratory
compromise or if pleural fluid is consistent
with empyema if the patient has respiratory
compromise or if pleural fluid is consistent
with empyema

Large: opacifies more than
half of the hemithorax

Bacterial culture and/or Gram
stain results positive
(empyema)

High

Yes in most cases

a

VATS, video-assisted thoracoscopic surgery.

61. Antigen testing or nucleic acid amplification through
polymerase chain reaction (PCR) increase the detection of
pathogens in pleural fluid and may be useful for management.
(strong recommendation; moderate-quality evidence)
62. Analysis of pleural fluid parameters, such as pH and
levels of glucose, protein, and lactate dehydrogenase, rarely
change patient management and are not recommended. (weak
recommendation; very low-quality evidence)
63. Analysis of the pleural fluid white blood cell (WBC) count,
with cell differential analysis, is recommended primarily to help
differentiate bacterial from mycobacterial etiologies and from
malignancy. (weak recommendation; moderate-quality evidence)
XII. What Are the Drainage Options for Parapneumonic Effusions?

Recommendations
64. Small, uncomplicated parapneumonic effusions
should not routinely be drained and can be treated with
antibiotic therapy alone. (strong recommendation; moderatequality evidence)
65. Moderate parapneumonic effusions associated with
respiratory distress, large parapneumonic effusions, or
documented purulent effusions should be drained. (strong
recommendation; moderate-quality evidence)
66. Both chest thoracostomy tube drainage with the addition
of fibrinolytic agents and VATS have been demonstrated to be
effective methods of treatment. The choice of drainage procedure
depends on local expertise. Both of these methods are associated
with decreased morbidity compared with chest tube drainage
alone. However, in patients with moderate-to-large effusions that

are free flowing (no loculations), placement of a chest tube
without fibrinolytic agents is a reasonable first option. (strong
recommendation; high-quality evidence)
XIII. When Should VATS or Open Decortication Be Considered in
Patients Who Have Had Chest Tube Drainage, With or Without
Fibrinolytic Therapy?

Recommendation
67. VATS should be performed when there is persistence of
moderate-large effusions and ongoing respiratory compromise
despite 2–3 days of management with a chest tube and
completion of fibrinolytic therapy. Open chest débridement
with decortication represents another option for management
of these children but is associated with higher morbidity rates.
(strong recommendation; low-quality evidence)
XIV. When Should a Chest Tube Be Removed Either After Primary
Drainage or VATS?

68. A chest tube can be removed in the absence of an
intrathoracic air leak and when pleural fluid drainage is
,1 mL/kg/24 h, usually calculated over the last 12 hours.
(strong recommendation; very low-quality evidence)
XV. What Antibiotic Therapy and Duration Is Indicated for the
Treatment of Parapneumonic Effusion/Empyema?

Recommendations
69. When the blood or pleural fluid bacterial culture identifies
a pathogenic isolate, antibiotic susceptibility should be used to
determine the antibiotic regimen. (strong recommendation; highquality evidence)
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Figure 1. Management of pneumonia with parapneumonic effusion; abx, antibiotics; CT, computed tomography; dx, diagnosis; IV, intravenous; US,
ultrasound; VATS, video-assisted thoracoscopic surgery.

70. In the case of culture-negative parapneumonic effusions,
antibiotic selection should be based on the treatment
recommendations for patients hospitalized with CAP (see
Evidence Summary for Recommendations 46–49). (strong
recommendation; moderate-quality evidence)
71. The duration of antibiotic treatment depends on the
adequacy of drainage and on the clinical response
demonstrated for each patient. In most children, antibiotic
treatment for 2–4 weeks is adequate. (strong recommendation;
low-quality evidence)
MANAGEMENT OF THE CHILD NOT
RESPONDING TO TREATMENT
XVI. What Is the Appropriate Management of a Child Who Is Not
Responding to Treatment for CAP?

Recommendation
72. Children who are not responding to initial therapy after
48–72 hours should be managed by one or more of the following:
628
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a. Clinical and laboratory assessment of the current
severity of illness and anticipated progression in order to
determine whether higher levels of care or support are
required. (strong recommendation; low-quality evidence)
b. Imaging evaluation to assess the extent and progression
of the pneumonic or parapneumonic process. (weak
recommendation; low-quality evidence)
c. Further investigation to identify whether the original
pathogen persists, the original pathogen has developed
resistance to the agent used, or there is a new secondary
infecting agent. (weak recommendation; low-quality
evidence)
73. A BAL specimen should be obtained for Gram stain and
culture for the mechanically ventilated child. (strong
recommendation; moderate-quality evidence)
74. A percutaneous lung aspirate should be obtained for Gram
stain and culture in the persistently and seriously ill child for
whom previous investigations have not yielded a microbiologic
diagnosis. (weak recommendation; low-quality evidence)

75. An open lung biopsy for Gram stain and culture should
be obtained in the persistently and critically ill, mechanically
ventilated child in whom previous investigations have not
yielded a microbiologic diagnosis. (weak recommendation;
low-quality evidence)
XVII. How Should Nonresponders With Pulmonary Abscess or
Necrotizing Pneumonia Be Managed?

Recommendation
76. A pulmonary abscess or necrotizing pneumonia identified
in a nonresponding patient can be initially treated with
intravenous antibiotics. Well-defined peripheral abscesses
without connection to the bronchial tree may be drained under
imaging-guided procedures either by aspiration or with a drainage
catheter that remains in place, but most abscesses will drain
through the bronchial tree and heal without surgical or invasive
intervention. (weak recommendation; very low-quality evidence)

DISCHARGE CRITERIA
XVIII. When Can a Hospitalized Child With CAP Be Safely
Discharged?

Recommendations
77. Patients are eligible for discharge when they have
documented overall clinical improvement, including level of
activity, appetite, and decreased fever for at least 12–24 hours.
(strong recommendation; very low-quality evidence)
78. Patients are eligible for discharge when they demonstrate
consistent pulse oximetry measurements .90% in room air
for at least 12–24 hours. (strong recommendation; moderatequality evidence)
79. Patients are eligible for discharge only if they demonstrate
stable and/or baseline mental status. (strong recommendation;
very low-quality evidence)
80. Patients are not eligible for discharge if they have
substantially increased work of breathing or sustained tachypnea
or tachycardia (strong recommendation; high-quality evidence)
81. Patients should have documentation that they can tolerate
their home anti-infective regimen, whether oral or intravenous,
and home oxygen regimen, if applicable, before hospital
discharge. (strong recommendation; low-quality evidence)
82. For infants or young children requiring outpatient oral
antibiotic therapy, clinicians should demonstrate that parents
are able to administer and children are able to comply
adequately with taking those antibiotics before discharge.
(weak recommendation; very low-quality evidence)
83. For children who have had a chest tube and meet the
requirements listed above, hospital discharge is appropriate
after the chest tube has been removed for 12–24 hours, either
if there is no clinical evidence of deterioration since removal or

if a chest radiograph, obtained for clinical concerns, shows
no significant reaccumulation of a parapneumonic effusion
or pneumothorax. (strong recommendation; very low-quality
evidence)
84. In infants and children with barriers to care, including
concern about careful observation at home, inability to comply
with therapy, or lack of availability for follow-up, these issues
should be identified and addressed before discharge. (weak
recommendation; very low-quality evidence)
XIX. When Is Parenteral Outpatient Therapy Indicated, In
Contrast to Oral Step-Down Therapy?

Recommendations
85. Outpatient parenteral antibiotic therapy should be
offered to families of children no longer requiring skilled
nursing care in an acute care facility but with a demonstrated
need for ongoing parenteral therapy. (weak recommendation;
moderate-quality evidence)
86. Outpatient parenteral antibiotic therapy should be
offered through a skilled pediatric home nursing program
or through daily intramuscular injections at an appropriate
pediatric outpatient facility. (weak recommendation; low-quality
evidence)
87. Conversion to oral outpatient step-down therapy when
possible, is preferred to parenteral outpatient therapy. (strong
recommendation; low-quality evidence)

PREVENTION
XX. Can Pediatric CAP Be Prevented?

Recommendations
88. Children should be immunized with vaccines for bacterial
pathogens, including S. pneumoniae, Haemophilus influenzae
type b, and pertussis to prevent CAP. (strong recommendation;
high-quality evidence)
89. All infants $6 months of age and all children and
adolescents should be immunized annually with vaccines for
influenza virus to prevent CAP. (strong recommendation; highquality evidence)
90. Parents and caretakers of infants ,6 months of age,
including pregnant adolescents, should be immunized with
vaccines for influenza virus and pertussis to protect the infants
from exposure. (strong recommendation; weak-quality evidence)
91. Pneumococcal CAP after influenza virus infection is
decreased by immunization against influenza virus. (strong
recommendation; weak-quality evidence)
92. High-risk infants should be provided immune prophylaxis
with respiratory syncytial virus (RSV)–specific monoclonal antibody to decrease the risk of severe pneumonia and hospitalization
caused by RSV. (strong recommendation; high-quality evidence)
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